Immunological Medicine最新文献_第7页

Macrophage activation syndrome associated with multi-system inflammatory syndrome in children: a case report and cytokine profile. 儿童巨噬细胞激活综合征与多系统炎症综合征相关：病例报告和细胞因子分析

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-09-13 DOI: 10.1080/25785826.2025.2559458

Yuji Fujita, Masaki Shimizu, Sayaka Aihara, Kohei Nomura, Shinya Yoshihara, Kaori Sekine, Maho Hatano, Shuya Kaneko, Hideaki Shiraishi

{"title":"Macrophage activation syndrome associated with multi-system inflammatory syndrome in children: a case report and cytokine profile.","authors":"Yuji Fujita, Masaki Shimizu, Sayaka Aihara, Kohei Nomura, Shinya Yoshihara, Kaori Sekine, Maho Hatano, Shuya Kaneko, Hideaki Shiraishi","doi":"10.1080/25785826.2025.2559458","DOIUrl":"10.1080/25785826.2025.2559458","url":null,"abstract":"Macrophage activation syndrome (MAS) is a potentially life-threatening complication requiring early diagnosis and prompt treatment in rheumatic diseases such as systemic juvenile idiopathic arthritis (sJIA). Recently, multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was reported to be complicated by MAS. The diagnostic criteria for MAS-associated MIS-C (MIS-C/MAS) remain unknown. We report the case of a 12-year-old boy who presented with fever for 4 days, swollen cervical lymph nodes, conjunctival congestion, red lips, strawberry tongue, irregular erythematous lesions, abdominal pain, and diarrhoea; he had coronavirus disease 2019 (COVID-19) 1 month prior. The patient was diagnosed MIS-C/MAS based on the criteria for sJIA/MAS, treated with intravenous immunoglobulin, glucocorticoids, and cyclosporine without any coronary artery sequelae. Evaluation of the patient's serum cytokine profile revealed that CXCL9 level (14259 pg/mL, reference range <31-83 pg/mL) was significantly elevated, as in sJIA/MAS. Based on cytokine profiles, the diagnostic criteria for MIC-S/MAS may be consistent with those for sJIA/MAS. No previous studies have reported on the cytokine profiles of MIS-C/MAS. Pediatricians should consider that MIS-C may complicate MAS, such as sJIA. Glucocorticoids and cyclosporine may be considered in cases of MIS-C complicated by MAS.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"115-119"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145055876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-10-11 DOI: 10.1080/25785826.2025.2565020

Yui Kosumi, Ryoko Asano, Aki Sugano, Masaru Yoshimura, Ryo Hisada, Michihito Kono, Yuichiro Fujieda, Tatsuya Atsumi, Masaru Kato

{"title":"Factors related to seroconversion of anti-cyclic citrullinated peptide antibody after the onset of rheumatoid arthritis: a case-control study and systematic review.","authors":"Yui Kosumi, Ryoko Asano, Aki Sugano, Masaru Yoshimura, Ryo Hisada, Michihito Kono, Yuichiro Fujieda, Tatsuya Atsumi, Masaru Kato","doi":"10.1080/25785826.2025.2565020","DOIUrl":"10.1080/25785826.2025.2565020","url":null,"abstract":"Anti-cyclic citrullinated peptide (CCP) antibodies typically present before rheumatoid arthritis (RA) but appear (seroconvert) after disease onset in some patients. This study analyzed factors related to anti-CCP seroconversion. Fifty-six consecutive patients with anti-CCP negative RA were enrolled. The first determination of anti-CCP status was defined as the baseline. Anti-CCP was then reassessed with an interval of 77 (±41) months. Demographics and baseline characteristics were compared between patients with and without anti-CCP seroconversion. Moreover, relevant studies were systematically reviewed. Six of the 56 patients experienced anti-CCP seroconversion (<4.5-12.4 [8.5-65.7] U/mL). These patients were more likely to have interstitial lung disease and HLA-DRB1 shared epitope (SE) alleles and to use biological disease-modifying antirheumatic drugs (bDMARDs). From the systematic review and meta-analysis, bDMARDs, bone erosions, HLA-DRB1 SE and rheumatoid factor positivity were identified as factors related to anti-CCP seroconversion. By selectively screening for anti-citrullinated protein antibody responses, an expansion of the repertoire was observed after the onset of RA. The seroconversion of anti-CCP after the onset of RA is associated with the typical features of RA and may therefore represent an overlooked seropositive disease.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"76-87"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A new era in atopic dermatitis treatment and evolving therapeutic strategies. 特应性皮炎治疗的新时代和不断发展的治疗策略。

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-09-30 DOI: 10.1080/25785826.2025.2567133

Tetsuya Honda

引用次数: 0

Comparison of drug retention rates between TNF inhibitors and tocilizumab for Takayasu arteritis: a multicenter retrospective study. 肿瘤坏死因子抑制剂和托珠单抗治疗高须动脉炎的药物保留率比较：一项多中心回顾性研究。

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-09-11 DOI: 10.1080/25785826.2025.2557038

Takahiro Sugiyama, Shunsuke Furuta, Taro Iwamoto, Kei Ikeda, Shin-Ichiro Kagami, Yasuhiko Kita, Kazuhiro Kurasawa, Shigekazu Takahashi, Daiki Nakagomi, Masaki Hiraguri, Hiroshi Nakajima

{"title":"Comparison of drug retention rates between TNF inhibitors and tocilizumab for Takayasu arteritis: a multicenter retrospective study.","authors":"Takahiro Sugiyama, Shunsuke Furuta, Taro Iwamoto, Kei Ikeda, Shin-Ichiro Kagami, Yasuhiko Kita, Kazuhiro Kurasawa, Shigekazu Takahashi, Daiki Nakagomi, Masaki Hiraguri, Hiroshi Nakajima","doi":"10.1080/25785826.2025.2557038","DOIUrl":"10.1080/25785826.2025.2557038","url":null,"abstract":"Objective: We compared the drug retention rate of tumor necrosis factor (TNF) inhibitors (TNFi) and tocilizumab in Takayasu arteritis (TAK) as an index of balance between effectiveness and safety in a real-world setting.Method: We included 50 TAK patients who received biologics in nine hospitals. All patients fulfilled the 1990 American College of Rheumatology classification criteria for TAK. We retrospectively collected clinical information. We analyzed the drug retention rates and the reasons for discontinuation regarding TNFi and tocilizumab.Results: The prednisolone dose at the start of the first biologics was a median of 15 mg/day, and an immunosuppressant was used in 25 patients. Tocilizumab was the most frequent first biologics (64%). Twenty-seven of 32 patients continued on tocilizumab, and four of 18 patients continued on TNFi. The retention rate was significantly higher in tocilizumab than in TNFi (87.9% vs. 66.7% at one year, p = 0.024). The reasons for discontinuing tocilizumab were primary failure in two patients, and other reasons in three. The reasons for discontinuing TNFi were secondary failure in five patients, primary failure in four patients, and other reasons in five.Conclusion: Tocilizumab has a higher continuation rate than TNFi, suggesting that tocilizumab may have better benefit-risk balance for TAK patients.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"68-75"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Life-threatening refractory leukopenia in a patient with systemic lupus erythematosus successfully treated with rituximab. 利妥昔单抗成功治疗系统性红斑狼疮患者致生命的难治性白细胞减少。

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-09-17 DOI: 10.1080/25785826.2025.2563427

Shunichiro Hanai, Yoshiaki Kobayashi, Daiki Nakagomi

{"title":"Life-threatening refractory leukopenia in a patient with systemic lupus erythematosus successfully treated with rituximab.","authors":"Shunichiro Hanai, Yoshiaki Kobayashi, Daiki Nakagomi","doi":"10.1080/25785826.2025.2563427","DOIUrl":"10.1080/25785826.2025.2563427","url":null,"abstract":"Leukopenia can occur because of lymphopenia, neutropenia or both. Leukopenia appearing as a common hematological manifestation of systemic lupus erythematosus (SLE) is typically mild, but potentially life-threatening. However, no consensus has been reached on treatment strategies for severe leukopenia in SLE. An 18-year-old man was diagnosed with SLE based on fever, malar and discoid rash, leukopenia, hypocomplementemia, and a positive result for anti-nuclear antibodies. Despite administration of high-dose glucocorticoids combined with immunosuppressants (including intravenous cyclophosphamide, mycophenolate mofetil, tacrolimus, and azathioprine) and intravenous immunoglobulin G (IgG) treatment, leukocyte count declined to 50/μL, accompanied by positive anti-neutrophil IgG antibodies. Bone marrow biopsy revealed normocellular marrow without hemophagocytosis. The patient developed febrile dyspnea due to pulmonary infection. Administration of rituximab (375 mg/m2 weekly for 4 weeks) led to rapid, sustained recovery of leukocyte count. The patient then recovered from respiratory failure with anti-microbial therapy. Prednisolone was successfully tapered to 5 mg/day. This case suggests that rituximab may provide an effective therapeutic option for severe treatment-refractory leukopenia in SLE.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"120-124"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145081918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vogt-Koyanagi-Harada syndrome potentially associated with COVID-19 vaccination: a case report and literature review. Vogt-Koyanagi-Harada综合征可能与COVID-19疫苗接种相关：病例报告和文献综述

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-07-09 DOI: 10.1080/25785826.2025.2528331

Zhiqiang Cui, Yan Luo, Yanli Yi, Xuli Guo, Yuqi Liu, Xiang Wang, Xiaonan Liu

{"title":"Vogt-Koyanagi-Harada syndrome potentially associated with COVID-19 vaccination: a case report and literature review.","authors":"Zhiqiang Cui, Yan Luo, Yanli Yi, Xuli Guo, Yuqi Liu, Xiang Wang, Xiaonan Liu","doi":"10.1080/25785826.2025.2528331","DOIUrl":"10.1080/25785826.2025.2528331","url":null,"abstract":"To investigate the potential association between COVID-19 vaccination and Vogt-Koyanagi-Harada (VKH) syndrome, offering novel insights for the diagnosis and management of vaccine-related ocular disorders. A case report combined with a literature review was conducted. A 19-year-old male developing VKH after receiving the second dose of an inactivated COVID-19 vaccine was analyzed. Clinical features, treatment outcomes (glucocorticoid therapy with 2-year follow-up), and literature-based comparisons were evaluated. PubMed-indexed cases of vaccine-associated VKH were systematically reviewed, and causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale. The patient presented with bilateral blurred vision 14 days post-vaccination, diagnosed as VKH with retinal neuroepithelial detachment via fluorescein angiography (FFA) and optical coherence tomography (OCT). Oral prednisone (starting at 60 mg/day, tapered gradually)restored visual acuity to near-normal levels (OD: 20/40, OS: 20/33), consistent with the patient's reported baseline vision. Within 8 weeks, with no recurrence during follow-up. Literature analysis revealed vaccine-associated VKH symptoms typically emerged at a median of 8 days post-vaccination, aligning with the WHO's 40-day adverse event monitoring window. A Naranjo score of 4 indicated a probable vaccine-triggered immune response. COVID-19 vaccines may induce VKH via immune dysregulation mechanisms, particularly in genetically predisposed individuals. Although causality remains unconfirmed, clinicians should maintain vigilance for acute bilateral uveitis post-vaccination. Glucocorticoid therapy demonstrates efficacy in symptom resolution and relapse prevention. Enhanced active surveillance and mechanistic studies on vaccine-related ocular adverse events are warranted.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"88-101"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful tocilizumab monotherapy for multicentric Castleman disease complicated by rheumatoid arthritis and Sjögren's disease: a case-based literature review. 托珠单抗单药治疗多中心Castleman病合并类风湿关节炎和Sjögren病的成功：一项基于病例的文献综述

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-08-14 DOI: 10.1080/25785826.2025.2547444

Koji Suzuki, Mitsuhiro Akiyama, Koichi Saito, Kanako Shimanuki, Yuko Kaneko

引用次数: 0

Muscle strength recovery in patients with idiopathic inflammatory myopathy with different myositis-specific autoantibodies. 具有不同肌炎特异性自身抗体的特发性炎性肌病患者的肌力恢复。

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-07-29 DOI: 10.1080/25785826.2025.2537472

Naoki Mugii, Yasuhito Hamaguchi, Fujiko Someya, Pleiades Tiharu Inaoka, Sho Horie, Natsumi Fushida, Tasuku Kitano, Ko Fujii, Jiro Nishio, Kyosuke Oishi, Takashi Matsushita

{"title":"Muscle strength recovery in patients with idiopathic inflammatory myopathy with different myositis-specific autoantibodies.","authors":"Naoki Mugii, Yasuhito Hamaguchi, Fujiko Someya, Pleiades Tiharu Inaoka, Sho Horie, Natsumi Fushida, Tasuku Kitano, Ko Fujii, Jiro Nishio, Kyosuke Oishi, Takashi Matsushita","doi":"10.1080/25785826.2025.2537472","DOIUrl":"10.1080/25785826.2025.2537472","url":null,"abstract":"This study aims to assess muscle strength recovery in patients with idiopathic inflammatory myopathy (IIM) with three myositis-specific autoantibodies (MSAs). Forty-eight IIM patients (19 with anti-TIF1-γ Ab, 21 with anti-ARS Ab, and 8 with anti-SRP Ab) were included. Physical exercise began one week after starting medication. Muscle strength was measured using a hand held dynamometer. CK levels, muscle strength recovery, manual muscle test 8 (MMT8), and the Barthel index (BI) scores were evaluated before and after treatment among patients with anti-TIF1-γ, anti-ARS or anti-SRP Abs. CK levels decreased after one week of medication, and physical exercise did not worsen muscle involvement. Patients with anti-TIF1-γ and anti-ARS Abs exhibited rapid muscle strength improvement, while those with anti-SRP Ab had slower recovery. MMT8 followed a similar trend. BI scores significantly improved in patients with anti-TIF1-γ and anti-ARS Abs. All eight patients with anti-SRP Ab achieved a BI score of 100 despite no significant changes due to high variability. Muscle strength improved significantly, even in patients with a BI score ≤ 60. Muscle strength was recovered regardless of their MSA profile, and physical exercise may be safe for restoring muscle strength.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"59-67"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid resolution of fever and panniculitis after anifrolumab in a patient with systemic lupus erythematosus refractory to standard immunosuppression. 对标准免疫抑制难治性系统性红斑狼疮患者进行无瘤单抗治疗后发热和全身炎的快速缓解。

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-08-06 DOI: 10.1080/25785826.2025.2543612

Shunichiro Hanai, Yoshiaki Kobayashi, Taro Iwamoto, Daiki Nakagomi

{"title":"Rapid resolution of fever and panniculitis after anifrolumab in a patient with systemic lupus erythematosus refractory to standard immunosuppression.","authors":"Shunichiro Hanai, Yoshiaki Kobayashi, Taro Iwamoto, Daiki Nakagomi","doi":"10.1080/25785826.2025.2543612","DOIUrl":"10.1080/25785826.2025.2543612","url":null,"abstract":"Anifrolumab, a monoclonal antibody against type I interferon (IFN) receptor, has shown high efficacy against systemic lupus erythematosus (SLE) in clinical trials. Although rapid effects of anifrolumab against cutaneous manifestations of SLE have been reported, efficacy has still been considered to take a month or more, and shorter-term efficacy has not been described. A 29-year-old Japanese woman developed fever, erythema on the trunk and both upper and lower extremities, cytopenia, pericardial effusion, and acute confusional state and was diagnosed with SLE. Intravenous methylprednisolone pulse therapy followed by oral prednisolone at 50 mg/day improved her confusional state. Intravenous cyclophosphamide at 500 mg was added, and prednisolone was reduced to 40 mg/day. Fever and erythema on the upper extremities recurred shortly afterwards. Skin biopsy revealed panniculitis. After intravenously administering a single 300-mg dose of anifrolumab, fever resolved within a day, and erythema entirely disappeared within about 2 weeks. The serum IFN-α concentration decreased significantly after a single infusion of anifrolumab. Anifrolumab infusions every 4 weeks were continued, then prednisolone was tapered to 1 mg/day under anifrolumab therapy over 22 months. Anifrolumab may provide improvement on a daily basis even in patients refractory to the standard of care.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"102-106"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment. 长冠肺炎：疾病机制、多系统后遗症和治疗前景。

IF 2.9

Immunological Medicine Pub Date : 2026-03-01 Epub Date: 2025-10-21 DOI: 10.1080/25785826.2025.2570902

Seiya Oba, Tadashi Hosoya, Hideyuki Iwai, Shinsuke Yasuda

{"title":"Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment.","authors":"Seiya Oba, Tadashi Hosoya, Hideyuki Iwai, Shinsuke Yasuda","doi":"10.1080/25785826.2025.2570902","DOIUrl":"10.1080/25785826.2025.2570902","url":null,"abstract":"Long COVID has emerged as a significant global health issue, affecting individuals across a wide spectrum of initial disease severity. While its definition and prevalence vary across studies, persistent symptoms such as fatigue, cognitive dysfunction, respiratory difficulties, and cardiovascular complications have been widely reported. Multiple pathophysiological mechanisms have been proposed, including incomplete viral clearance, reactivation of latent viruses, immune dysregulation, autoimmunity, endothelial dysfunction, microbiome alterations, and mitochondrial impairment. These interconnected processes are thought to contribute to chronic inflammation and multi-organ disease. To date, there are no established therapies for Long COVID, and management primarily focuses on symptomatic relief and rehabilitation. Vaccination has been shown to reduce the incidence of Long COVID, and emerging strategies, including antiviral agents, immune-modulating therapies, microbiome restoration, and mitochondria-targeted interventions, are under investigation. This review summarizes the current understanding of the epidemiology, pathophysiology, organ-specific manifestations, and potential therapeutic approaches for Long COVID, aiming to provide insights into future research directions and clinical management strategies.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"35-58"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145337691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0